Company intelligence / Profile preview
Roshon Therapeutics
Scarsdale, New York, USAroshontx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Roshon Therapeutics is developing first-in-class monoclonal antibodies against novel targets on myeloid cells. The company’s approach aims to address unmet needs in blood cancers and potentially expand into solid tumors and autoimmune diseases. Early data are promising, with a focus on innovative immuno-oncology strategies distinct from existing therapies targeting lymphoid cells like PD1.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Roshon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roshon Therapeutics.